Viking Thera (VKTX) Stock Price, Quote & News

Company Profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 704 4660

Website: www.vikingtherapeutics.com

Address:

9920 Pacific Heights Boulevard, Suite 350, San Diego, United States

JohnnyVacs Jun. 16 at 7:52 PM

$VKTX lmao. Who would’ve guessed. All on 200k volume. Only took 700k to get the 30.30. But naa 200k to drop it all the way back to red. As always, sell the pops, it’ll always work.

0 · Reply

bobby1084 Jun. 16 at 7:51 PM

$VKTX 200 more $29.7

0 · Reply

Georgejj Jun. 16 at 7:29 PM

$VKTX https://finance.yahoo.com/markets/stocks/articles/viking-therapeutics-stock-going-100-053500702.html Good luck and GOD bless,

0 · Reply

ians Jun. 16 at 7:03 PM

$VKTX Congrats to buyers who loaded up sub $30. 👍 VK2735 SC maintenance trial due 3Q. Get ready for WS $70-125 PT 😎☘️💎

2 · Reply

Muddymac Jun. 16 at 6:52 PM

$VKTX As I travel around the country for work, I realize that we have no shortage of the TAM. Plenty of potential patients to go around.

1 · Reply

chuckieclam Jun. 16 at 6:21 PM

$VKTX 30 good

0 · Reply

uaglio Jun. 16 at 6:01 PM

$VKTX it will run…

0 · Reply

saifnila2 Jun. 16 at 5:58 PM

$VKTX it will run up to 42 in the next month or two prior to release of maintenance trial. The question is whether you should sell a little bit prior to data release , as you very well know the fukery of the manipulators. I would not take it for granted that it will run after the trial.

0 · Reply

vijaykamat14 Jun. 16 at 5:54 PM

$VKTX above $30 super

0 · Reply

NYG4ever Jun. 16 at 5:45 PM

$VKTX Resistance to become support - we have work to do, but a path back to $31 in the interim.

0 · Reply

Viking Therapeutics management to meet with B. Riley

2026-06-11T11:11:15.000Z - 5 days ago

Viking Therapeutics names Hubert Chen, M.D., as Chief Medical Officer

Jun 11, 2026, 7:05 AM EDT - 5 days ago

Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D.

Jun 7, 2026, 7:00 AM EDT - 9 days ago

Viking Therapeutics Slides: Corporate presentation

Jun 4, 2026, 1:25 PM EDT - 12 days ago

Viking Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

2026-05-28T13:23:51.000Z - 19 days ago

Viking Therapeutics initiated with a Buy at Lake Street

2026-05-27T15:22:10.000Z - 20 days ago

Viking Therapeutics assumed with a Buy at Truist

May 21, 2026, 7:05 AM EDT - 26 days ago

Viking Therapeutics to Participate at Upcoming Investor Conferences

2026-05-12T12:50:07.000Z - 5 weeks ago

Viking Therapeutics’ VK2735 demonstrates wieght loss in Phase 2 trial

May 12, 2026, 7:05 AM EDT - 5 weeks ago

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

ECO

May 5, 2026, 7:05 AM EDT - 6 weeks ago

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026

ECO

2026-04-30T17:16:19.000Z - 6 weeks ago

Viking Therapeutics price target lowered to $100 from $105 at Cantor Fitzgerald

2026-04-30T14:12:18.000Z - 6 weeks ago

Viking Therapeutics price target lowered to $95 from $99 at Morgan Stanley

2026-04-29T21:38:53.000Z - 6 weeks ago

Viking Therapeutics reports Q1 EPS ($1.37), consensus (91c)

Apr 29, 2026, 4:30 PM EDT - 6 weeks ago

Viking Therapeutics Earnings Call Transcript: Q1 2026

Apr 29, 2026, 4:30 PM EDT - 6 weeks ago

Viking Therapeutics Earnings release: Q1 2026

Apr 29, 2026, 4:30 PM EDT - 6 weeks ago

Viking Therapeutics Quarterly report: Q1 2026

Apr 29, 2026, 4:05 PM EDT - 6 weeks ago

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Apr 22, 2026, 4:35 PM EDT - 7 weeks ago

Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026

Apr 1, 2026, 8:00 AM EDT - 2 months ago

Viking Therapeutics Proxy statement: Proxy filing

Apr 1, 2026, 8:00 AM EDT - 2 months ago

Viking Therapeutics Proxy statement: Proxy filing

2026-03-26T11:11:25.000Z - 2 months ago

Viking Therapeutics completes enrollment in Phase 3 VANQUISH-2 trial of VK2735

Mar 26, 2026, 7:05 AM EDT - 2 months ago

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

Mar 13, 2026, 7:00 AM EDT - 3 months ago

Viking Therapeutics Slides: Corporate presentation

Mar 10, 2026, 10:40 AM EDT - 3 months ago

Viking Therapeutics Transcript: Leerink Global Healthcare Conference 2026

2026-03-03T17:37:55.000Z - 3 months ago

Viking Therapeutics management to meet with Truist

2026-02-23T17:07:01.000Z - 4 months ago

Viking Therapeutics rises 10.7%

2026-02-12T13:20:55.000Z - 4 months ago

Viking Therapeutics price target lowered to $99 from $102 at Morgan Stanley

Feb 11, 2026, 5:10 PM EST - 4 months ago

Viking Therapeutics plans to advance oral obesity drug to late-stage trial

Feb 11, 2026, 4:30 PM EST - 4 months ago

Viking Therapeutics Earnings Call Transcript: Q4 2025

Feb 11, 2026, 4:30 PM EST - 4 months ago

Viking Therapeutics Annual report: Q4 2025

Feb 11, 2026, 4:30 PM EST - 4 months ago

Viking Therapeutics Earnings release: Q4 2025

Feb 11, 2026, 4:16 PM EST - 4 months ago

Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Feb 4, 2026, 4:05 PM EST - 4 months ago

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026

Feb 3, 2026, 1:27 PM EST - 4 months ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN GPCR LLY NVO PFE

Jan 14, 2026, 7:00 AM EST - 5 months ago

Viking Therapeutics Slides: Corporate presentation

Jan 12, 2026, 7:19 PM EST - 5 months ago

Appetite for weight-loss deals broader than visible, Viking CEO says

Jan 12, 2026, 5:15 PM EST - 5 months ago

Viking Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 5 months ago

Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity

Jan 8, 2026, 7:00 AM EST - 5 months ago

Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity

Jan 7, 2026, 7:00 AM EST - 5 months ago

Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer

Jan 5, 2026, 4:03 PM EST - 5 months ago

Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 10:57 AM EST - 5 months ago

Novo Nordisk's weight-loss pill is available. Here's why Lilly's and Viking's stocks are down.

LLY NVO

Dec 9, 2025, 7:00 AM EST - 6 months ago

Viking Therapeutics Slides: Corporate presentation

Nov 25, 2025, 4:05 PM EST - 7 months ago

Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference

Nov 19, 2025, 7:00 AM EST - 7 months ago

Viking Therapeutics Slides: Corporate Presentation

Nov 19, 2025, 3:00 AM EST - 7 months ago

Viking Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 2:55 AM EST - 7 months ago

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735

Nov 6, 2025, 7:05 AM EST - 7 months ago

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025

Oct 29, 2025, 4:05 PM EDT - 8 months ago

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025

Oct 22, 2025, 4:30 PM EDT - 8 months ago

Viking Therapeutics Earnings Call Transcript: Q3 2025

Oct 22, 2025, 4:30 PM EDT - 8 months ago

Viking Therapeutics Quarterly report: Q3 2025

Oct 22, 2025, 4:30 PM EDT - 8 months ago

Viking Therapeutics Earnings release: Q3 2025

Oct 22, 2025, 4:05 PM EDT - 8 months ago

Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 21, 2025, 7:05 AM EDT - 8 months ago

Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity

Oct 15, 2025, 4:05 PM EDT - 8 months ago

Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025

Oct 1, 2025, 7:00 AM EDT - 9 months ago

Viking Therapeutics Slides: Corporate Presentation

Sep 23, 2025, 11:20 AM EDT - 9 months ago

Viking Therapeutics Transcript: Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

Sep 8, 2025, 3:20 PM EDT - 10 months ago

Viking Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 20, 2025, 9:50 AM EDT - 10 months ago

Viking Therapeutics: What's Happening With VKTX Stock?

Aug 19, 2025, 9:38 PM EDT - 10 months ago

Why Viking Therapeutics stock reaction to obesity pill data is wildly ‘overdone'

Aug 19, 2025, 6:27 PM EDT - 10 months ago

Mizuho's Jared Holz talks Viking Therapeutics' massive stock drop on obesity pill data

Aug 19, 2025, 1:45 PM EDT - 10 months ago

The market reaction is overdone on Viking Therapeutics, says BTIG's Justin Zelin

Aug 19, 2025, 12:19 PM EDT - 10 months ago

Viking Therapeutics plummets on new obesity drug data. Here's a breakdown

Aug 19, 2025, 12:05 PM EDT - 10 months ago

Viking Therapeutics Stock Plunges on Oral Weight-Loss Pill Study Results

Aug 19, 2025, 11:00 AM EDT - 10 months ago

Viking Therapeutics Shares Nosedive Toward Worst Day Ever After Obesity Trial Data

Aug 19, 2025, 9:39 AM EDT - 10 months ago

Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data

Aug 19, 2025, 9:11 AM EDT - 10 months ago

Viking Therapeutics' stock tumbles after results of oral weight-loss drug trial. It has company.

Aug 19, 2025, 8:57 AM EDT - 10 months ago

Viking Therapeutics stock tumbles 37% today, but here's why you should ‘HOLD'

Aug 19, 2025, 8:00 AM EDT - 10 months ago

Viking Therapeutics Transcript: Study Result

Aug 19, 2025, 8:00 AM EDT - 10 months ago

Viking Therapeutics Press release: Study Result

Aug 19, 2025, 7:18 AM EDT - 10 months ago

Viking Therapeutics' oral weight-loss pill meets expectations in mid-stage study

Aug 19, 2025, 7:08 AM EDT - 10 months ago

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

Jul 23, 2025, 4:30 PM EDT - 11 months ago

Viking Therapeutics Earnings Call Transcript: Q2 2025

Jul 23, 2025, 4:30 PM EDT - 11 months ago

Viking Therapeutics Quarterly report: Q2 2025

Jul 23, 2025, 4:30 PM EDT - 11 months ago

Viking Therapeutics Earnings release: Q2 2025

Jul 23, 2025, 4:05 PM EDT - 11 months ago

Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 16, 2025, 4:05 PM EDT - 11 months ago

Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025

Jul 3, 2025, 7:00 AM EDT - 1 year ago

Viking Therapeutics Slides: Corporate Presentation

Jun 25, 2025, 7:03 AM EDT - 1 year ago

Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735

Jun 23, 2025, 6:10 PM EDT - 1 year ago

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

AMGN GPCR LLY NVO PFE REGN XBI

Jun 14, 2025, 7:00 AM EDT - 1 year ago

Viking Therapeutics Slides: Corporate Presentation

Jun 5, 2025, 11:40 AM EDT - 1 year ago

Viking Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 2, 2025, 7:00 AM EDT - 1 year ago

Viking Therapeutics Slides: Company Presentation

Apr 23, 2025, 4:30 PM EDT - 1 year ago

Viking Therapeutics Earnings Call Transcript: Q1 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

Viking Therapeutics Quarterly report: Q1 2025

Apr 23, 2025, 4:30 PM EDT - 1 year ago

Viking Therapeutics Earnings release: Q1 2025

Apr 23, 2025, 4:05 PM EDT - 1 year ago

Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Viking Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Viking Therapeutics Proxy statement: Proxy Filing

Apr 15, 2025, 3:26 PM EDT - 1 year ago

Will Pfizer approach Viking Therapeutics with a buyout proposal?

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Viking Therapeutics Proxy statement: Proxy Filing

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Viking Therapeutics Proxy statement: Proxy Filing

Mar 26, 2025, 7:05 AM EDT - 1 year ago

Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

Mar 12, 2025, 11:54 AM EDT - 1 year ago

Viking Therapeutics' new contract is a game changer. Here's how much money it could bring in.

Mar 11, 2025, 9:20 AM EDT - 1 year ago

Viking Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 11, 2025, 7:03 AM EDT - 1 year ago

Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735

Feb 6, 2025, 7:00 AM EST - 1 year ago

Viking Therapeutics Slides: Corporate Presentation

Feb 5, 2025, 4:30 PM EST - 1 year ago

Viking Therapeutics Earnings Call Transcript: Q4 2024

Feb 5, 2025, 4:30 PM EST - 1 year ago

Viking Therapeutics Annual report: Q4 2024

Feb 5, 2025, 4:30 PM EST - 1 year ago

Viking Therapeutics Earnings release: Q4 2024

Feb 5, 2025, 4:05 PM EST - 1 year ago

Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Jan 29, 2025, 4:05 PM EST - 1 year ago

Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025

Jan 23, 2025, 7:38 AM EST - 1 year ago

Why this Weight-Loss Drug Stock Could Gain 200%

Jan 23, 2025, 7:00 AM EST - 1 year ago

Viking Therapeutics Slides: Corporate Presentation

Jan 21, 2025, 3:04 PM EST - 1 year ago

What's next for Viking Therapeutics? Here's how the company can scale up.

JohnnyVacs Jun. 16 at 7:52 PM

$VKTX lmao. Who would’ve guessed. All on 200k volume. Only took 700k to get the 30.30. But naa 200k to drop it all the way back to red. As always, sell the pops, it’ll always work.

0 · Reply

bobby1084 Jun. 16 at 7:51 PM

$VKTX 200 more $29.7

0 · Reply

Georgejj Jun. 16 at 7:29 PM

$VKTX https://finance.yahoo.com/markets/stocks/articles/viking-therapeutics-stock-going-100-053500702.html Good luck and GOD bless,

0 · Reply

ians Jun. 16 at 7:03 PM

$VKTX Congrats to buyers who loaded up sub $30. 👍 VK2735 SC maintenance trial due 3Q. Get ready for WS $70-125 PT 😎☘️💎

2 · Reply

Muddymac Jun. 16 at 6:52 PM

$VKTX As I travel around the country for work, I realize that we have no shortage of the TAM. Plenty of potential patients to go around.

1 · Reply

chuckieclam Jun. 16 at 6:21 PM

$VKTX 30 good

0 · Reply

uaglio Jun. 16 at 6:01 PM

$VKTX it will run…

0 · Reply

saifnila2 Jun. 16 at 5:58 PM

0 · Reply

vijaykamat14 Jun. 16 at 5:54 PM

$VKTX above $30 super

0 · Reply

NYG4ever Jun. 16 at 5:45 PM

$VKTX Resistance to become support - we have work to do, but a path back to $31 in the interim.

0 · Reply

BeyondtheCouch Jun. 16 at 5:43 PM

$VKTX retail kiddie shorts waiting to type that it can’t hold $30. Itchy fingers!

0 · Reply

Twitgb Jun. 16 at 5:40 PM

$VKTX seems like a strategy.

2 · Reply

JohnnyVacs Jun. 16 at 5:39 PM

$VKTX also 100k buys moving this up 20 cents. And 6k shares dropping it 15 cents lol. I kinda like this movement. I think shorts are starting to panic a little. Liquidity is tight. 3-5 big buys and this could be gone.

1 · Reply

Chi_Booth Jun. 16 at 5:32 PM

$VKTX Is it happening?

1 · Reply

JohnnyVacs Jun. 16 at 5:32 PM

$VKTX forgot to add.

0 · Reply

JohnnyVacs Jun. 16 at 5:31 PM

$VKTX ive never seen a stock that so badly wants to go up but is constantly dragged right back down. Shorts just won’t give up lol. Pops and just instantly sells back down. One day we can only hope it doesn’t stop.

0 · Reply

Twitgb Jun. 16 at 5:31 PM

$VKTX and over 30.

0 · Reply

Twitgb Jun. 16 at 5:29 PM

$VKTX it is nice kyle, isnt it.

0 · Reply

NYG4ever Jun. 16 at 5:26 PM

$VKTX $30 Kyle must have fell off his dinousaur seeing that

0 · Reply

SlimyMango Jun. 16 at 5:19 PM

$VKTX Doing slightly better than XBI today 🤷‍♂️

1 · Reply

vu_jade Jun. 16 at 4:29 PM

$VKTX still a great buy under $30 And we’ve been under this level a long time this year .. Hell it’s a buy under $43 … #SKOL

0 · Reply

NYG4ever Jun. 16 at 3:51 PM

$VKTX you will be set free one day Charlie

2 · Reply

Market Cap	3.34B
Revenue (ttm)	0.00
Net Income (ttm)	-359.64M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	924,404
Avg Vol	2,155,342
Day's Range	N/A - N/A
Shares Out	116.11M
Stochastic %K	41%
Beta	0.69
Analysts	Strong Sell
Price Target	$91.88